Musings on genome medicine: Is there hope for ethical and safe stem cell therapeutics?

Genome Medicine

Volumn 1, Issue 7, 2009, Pages

  Rao, Mahendra ^a,b   Condic, Maureen L ^c  

^a Life Technologies Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DIFFERENTIATION; CELL SELECTION; CELL TYPE; CLONING; DNA MODIFICATION; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; FUNDING; GENOMICS; GOVERNMENT REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT TRANSFORMATION; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; UNITED STATES;

EID: 77953409410     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm70     Document Type: Note

References (25)

1. Alper J: Geron gets green light for human trial of ES cellderived product. Nat Biotechnol 2009, 27:213-214.
2. Morizane A, Li JY, Brundin P: From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tissue Res 2008, 331:323-336.
3. Ahrlund-Richter L, De Luca M, Marshak DR, Munsie M, Veiga A, Rao M: Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell 2009, 4: 20-26.
4. Rao M, Condic ML: Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. Stem Cells Dev 2008, 17:1-10.
5. Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA, Hermerén G, High KA, Kim HO, Lee HP, Levy-Lahad E, Li L, Lo B, Marshak DR, McNab A, Munsie M, Nakauchi H, Rao M, Rooke HM, Valles CS, Srivastava A, Sugarman J, Taylor PL, Veiga A, Wong AL, Zoloth L, Daley GQ: New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 2008, 3:607-609.
6. International Consortium of Stem Cell Networks: Global Regulation of Human Embryonic Stem Cell Research and Oocyte Donation [http://www.stemcellcentre.edu.au/PDF/ Global_Regulation_HESC_Research_Oocyte_Donation.pdf]
7. Condic M: Alternative sources of pluripotent stem cells: altered nuclear transfer. Cell Proliferation 2008, 41(Suppl 1): 7-19.
8. Holden C: Obama executive order. For Congress and NIH, headaches ahead on stem cells. Science 2009, 323:1552-1553.
9. National Institutes of Health guidelines for stem cell research [http://stemcells.nih.gov/policy/2009guidelines.htm]
10. Holden C, Kaiser J: Biomedical policy. Draft stem cell guidelines please many, disappoint some. Science 2009, 324:446.
11. Wilmut I: The first direct reprogramming of adult human fibroblasts. Cell Stem Cell 2007, 1:593-594.
12. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
13. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
14. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
15. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
16. Yamanaka S: A fresh look at iPS cells. Cell 2009, 137:13-17.
17. Lawrenz B, Schiller H, Willbold E, Ruediger M, Muhs A, Esser S: Highly sensitive biosafety model for stem-cell-derived grafts. Cytotherapy 2004, 6:212-222.
18. Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O: Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 2007, 25:2257-2268.
19. Nagano K, Yoshida Y, Isobe T: Cell surface biomarkers of embryonic stem cells. Proteomics 2008, 8:4025-4035.
20. Peh GS, Lang RJ, Pera MF, Hawes SM: CD133 expression by neural progenitors derived from human embryonic stem cells and its use for their prospective isolation. Stem Cells Dev 2009, 18:269-282.
21. Chung S, Shin BS, Hedlund E, Pruszak J, Ferree A, Kang UJ, Isacson O, Kim KS: Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006, 97:1467-1480.
22. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, Zheng L, Hentze H, Philp RJ, Oh SK, Yap M: Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008, 26:1454-1463.
23. St John JC, Alderson J: Stem-cell banking: the size of the task. Lancet 2005, 366:1991-1992.
24. Condic ML, Rao M: Regulatory issues for personalized pluripotent cells. Stem Cells 2008, 26:2753-2758.
25. Yamanaka S: Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007, 1:39-49.